Structure · schematic
Peptide chain · GLP-1-Analog
Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid.
Research areas*
* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.
Mechanism of action
- Mazdutide is a dual agonist at GLP-1 and glucagon receptors, derived from oxyntomodulin (OXM).
- The GLP-1 action governs insulin secretion and appetite, while the glucagon action is intended to address energy expenditure and hepatic fat metabolism.
- It is being developed mainly in Asia (Innovent/Eli Lilly) for obesity and type 2 diabetes.
Research status
- Mazdutide is in advanced clinical development, focused on Chinese study populations.
- A Phase III study published in 2025 (GLORY-1) in Chinese adults with obesity or overweight documented significant weight reductions versus placebo.
- Further Phase II/III studies are investigating efficacy and safety in obesity without diabetes.
- There is no approval outside China to date.
Evidence level
Cited studies
Known risks
- 01Safety profile not established outside the study populations
- 02Gastrointestinal side effects (nausea, diarrhoea, vomiting) common
- 03Glucagon agonism can affect heart rate and blood sugar
- 04Evidence base largely from one geographic population
- 05No long-term safety data available
Frequently asked questions
What is Mazdutid?
Mazdutide is a dual agonist at GLP-1 and glucagon receptors, derived from oxyntomodulin (OXM).
What type of peptide is Mazdutid?
Mazdutid belongs to the GLP-1 analog class.
Is Mazdutid legal in Germany?
Mazdutid is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Where can I buy Mazdutid?
Peptica sells nothing and names no sources. Mazdutid is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
Is Mazdutid banned in sport (WADA)?
Mazdutid is currently not on the WADA Prohibited List.
What are the known risks of Mazdutid?
Documented risks include: Safety profile not established outside the study populations; Gastrointestinal side effects (nausea, diarrhoea, vomiting) common. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is Mazdutid?
The evidence is classified as “early clinical studies”. 2 studies are cited on this page.
What is the molecular weight of Mazdutid?
Mazdutid has a molar mass of about 4476 Da, with a plasma half-life of ~6 days (once weekly).
Which peptides are related to Mazdutid?
Closely related entries: Tirzepatid, Retatrutid, Survodutid. A direct side-by-side comparison is available via the compare function.
Related entries
Legal status
Germany
not approvedAustria
not approvedSwitzerland
not approvedEU
not approvedUSA
not approvedCanada
not approvedLegal status varies by country and can change. This is not legal advice.
Sources & methodology
- 2 peer-reviewed studies cited, linked to PubMed where available.
- Molecular data verified against PubChem and primary literature. PubChem CID 167312357
- Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.
Last editorially reviewed: 30 May 2026
Legal assessment
Mazdutide has no approval in the EU, Germany or Switzerland. Obtaining it as a research chemical outside clinical studies is illegal and carries considerable safety risks.
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.
Anzeige
Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.